Standard therapy for multiple myeloma (MM) usually includes an autologous bone marrow stem
cell transplant - a procedure where the patient is treated with high dose chemotherapy and
then their own (autologous) stem cells are transplanted back into their body. Patients with
multiple myeloma and high risk genes, always relapse after an autologous transplant and
often die within two years from the time of their transplant. A different type of transplant
allogeneic) using donor cells, may work better for high-risk Multiple Myeloma, because the
donor cells may help kill the lymphoid cancer cells.
This study will investigate if a matched donor stem cell transplant using a newer, reduced
toxicity, chemotherapy (Flu-Bu4) is a feasible option for patients with high risk, Multiple
- Biologic high risk Multiple Myeloma:
- Stage II/III Multiple Myeloma, any of: t(4; 14), t(14; 16),(14:20) by Fish; 17P-
by conventional cytogenetics or Fish; ∆13 by conventional cytogenetics;
Hypodiploidy by conventional cytogenetics.
- Relapsed or persistent multiple myeloma after ASCT.
- Persistent multiple myeloma, regardless of previous therapies.
- Plasma cell leukemia, regardless of previous therapies.
- Age up to 70 years old (less than 71 years old at the date of transplant admission).
- Disease status: in CR, nCR, VGPR, PR or stable disease within 1 month of admission
- Patients with non-secretory and oligosecretory disease are eligible if they meet
certain criteria within 2 weeks prior to the transplant.
- Specific renal, liver, cardiac, and pulmonary function requirements(all must be met
within 30 days of transplant admission)
- Persistent invasive infections, not controlled by antimicrobials.
- HIV-1/HIV-2 or HTLV-1/HTLV-2 seropositivity.
- Uncontrolled medical or psychiatric disorder.
- No response or progressive disease at the time of transplantation.